The investigation whether Medsantek Laboratuar Malzemeleri San. ve Tic. Ltd. Şti. and Genomed Sağlık Hizmetleri A.Ş,which are authorized distributors of ThermoScientific’s DNA sequence analysis devices, abused their dominant position in the market for the said devices’ sales and maintenance in the market for kits used in those devices and violated the Act No. 4054 was concluded.

As a result of the discussion of the contents of the file on 28.03.2018, the Competition Board decided that Medsantek Laboratuar Malzemeleri San. ve Tic. Ltd. Şti violated article 6 of the Act no. 4054; therefore the undertaking concerned would be imposed administrative fines as per article 16 of the same Act. On the other hand, Genomed Sağlık Hizmetleri A.Ş.did not violate the Act no. 4054; thus, it was not necessary to impose administrative fines on the said undertaking.

Click here for the text of the pronouncement of the decision dated 28.03.2019 and numbered 19-13/182-80, the reasoned decision for which will be notified later and which can be appealed before Ankara Administrative Courts.